drugset / Trial / NCT01268280
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Phase 2
Terminated
32 enrolled
Cytokinetics
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
Timeline
- Start
- 2010-12
- Primary completion
- 2012-10
- Completion
- 2012-10
Outcome
Outcome not reported
Stopped (Enrollment): “Closed after complete treatment of 32 patients after 21 months' recruitment.”
Publications
- Results Sanders DB, Rosenfeld J, Dimachkie M, Meng L, Malik FI. A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses of Tirasemtiv in Patients with Myasthenia Gravis. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 2013
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tirasemtiv | Other / unclassified | 250 mg | Oral |
| Subject | tirasemtiv | Other / unclassified | 500 mg | Oral |